ReviewCurrent opinion in pulmonary medicine2015
Pneumonia in the neutropenic cancer patient.
Review in Current opinion in pulmonary medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
Community-acquired Pneumonia in Immunosuppressed Adult Patients: Observational, Perspective Study, ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)
Who cites it
35 citing papers in PubMed, 84 citations in OpenAlex.
- Article
- Does the severity of neutropenia affect mortality in bacteremic cancer patients?BMC infectious diseases · 2026Article
- Application of Metagenomic Next-Generation Sequencing in the Diagnosis of Pneumonia in Patients With Cancer.Cancer medicine · 2026Article
- International Consensus on Severe Lung Cancer-The Second Edition.Translational lung cancer research · 2026Review
- Adverse drug reactions associated with doxorubicin and epirubicin: A descriptive analysis from VigiBase.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2026Article
- A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for cabazitaxel.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Case Report: Necrotizing pulmonary destruction and fatal gangrene: the imperative of early recognition.Frontiers in medicine · 2026Article
- Impact of Neutropenia on Clinical Outcomes in Critically Ill Patients with Acute Respiratory Failure.Pulmonary therapy · 2025Article
- In-hospital mortality prognostication for cancer patients with febrile neutropenia.Communications medicine · 2025Article
- Neutrophil percentages in bronchoalveolar lavage fluid: Implications for diagnosing bacterial pneumonia in patients with immunocompromise and neutropenia.medRxiv : the preprint server for health sciences · 2024Article
- Blocking HXAmBio · 2024Article
- Blocking HXAbioRxiv : the preprint server for biology · 2024Article
- A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS).Frontiers in pharmacology · 2024Article
- Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- What Is Different in Acute Hematologic Malignancy-Associated ARDS? An Overview of the Literature.Medicina (Kaunas, Lithuania) · 2022Review
- Infectious diseases as a cause of death among cancer patients: a trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database.Infectious agents and cancer · 2021Article
- Deep learning computer-aided detection system for pneumonia in febrile neutropenia patients: a diagnostic cohort study.BMC pulmonary medicine · 2021Article
- International consensus on severe lung cancer-the first edition.Translational lung cancer research · 2021Review
- Clinical significance of microbial colonization identified by initial bronchoscopy in patients with lung cancer requiring chemotherapy.Journal of thoracic disease · 2021Article
- Infectious Disease Complications in Patients with Cancer.Critical care clinics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewPneumonia is the leading cause of death among neutropenic cancer patients, particularly those with acute leukaemia. Even with empiric therapy, case fatality rates of neutropenic pneumonias remain unacceptably high. However, recent advances in the management of neutropenic pneumonia offer hope for improved outcomes in the cancer setting. This review summarizes recent literature regarding the clinical presentation, microbiologic trends, diagnostic advances and therapeutic recommendations for cancer-related neutropenic pneumonia. RECENT
findingsAlthough neutropenic patients acquire pathogens both in community and nosocomial settings, patients' obligate healthcare exposures result in the frequent identification of multidrug-resistant bacterial organisms on conventional culture-based assessment of respiratory secretions. Modern molecular techniques, including expanded use of galactomannan testing, have further facilitated identification of fungal pathogens, allowing for aggressive interventions that appear to improve patient outcomes. Multiple interested societies have issued updated guidelines for antibiotic therapy of suspected neutropenic pneumonia. The benefit of antibiotic medications may be further enhanced by agents that promote host responses to infection. SUMMARY: Neutropenic cancer patients have numerous potential causes for pulmonary infiltrates and clinical deterioration, with lower respiratory tract infections among the most deadly. Early clinical suspicion, diagnosis and intervention for neutropenic pneumonia provide cancer patients' best hope for survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.